logo
Plus   Neg
Share
Email

Catalyst Pharma Inks Deal With Endo For Vigabatrin Tablets

Catalyst Pharmaceuticals Inc. (CPRX), Tuesay said it has inked a deal with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril (vigabatrin) tablets through Endo's U.S. Generic Pharmaceuticals segment.

Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.

Catalysts Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases.

"We are very happy to work with Endo, to bring generic Sabril® tablets to market. Endo is an established leader in the generic vigabatrin marketplace," said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. "Our search for an appropriate partner for this product was long but rewarding with this result. We look forward to bringing to market this important medication to improve the lives of patients."

"Generic vigabatrin tablets will complement our current powder vigabatrin offering and will expand the number of patients that can benefit from having access to a high-quality, generic vigabatrin option," said Brandon Rockwell, Senior Vice President, Business Development and Strategy of Endo.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Co. plans to invest $500 million in electric truck maker Rivian, the companies said Wednesday. They will also work together to develop an all-new battery electric vehicle for Ford using Rivian's skateboard platform. Ford's investment comes just months after Rivian revealed two new products, an all-electric pickup and SUV. AT&T Inc. (T) reported first-quarter adjusted earnings per share of $0.86 compared to $0.85, prior year. On average, 23 analysts polled by Thomson Reuters expected the company to report profit per share of $0.86 for the quarter. Analysts' estimates typically exclude special items. Adjusting for amortization,... Shares of Credit Suisse Group AG were gaining around 3 percent in Swiss trading after the banking major reported Wednesday higher profit in its first quarter, despite weak revenues. Looking ahead, the company said it is cautiously optimistic about its prospects for the second quarter of 2019. The company remains focused on increasing its returns over the course of 2019 and beyond.
Follow RTT